UBS/CALL/ROCHE GS/320.004/0.025/24.12.25 Share Price

Warrant

DROGVU

CH1164713914

Market Closed - Bid/Ask 16:20:00 26/06/2024 BST After market 16:15:00
0.12 CHF -11.11% Intraday chart for UBS/CALL/ROCHE GS/320.004/0.025/24.12.25 0.116 -3.33%
1 month+42.86%
3 months+50.00%
Date Price Change
26/06/24 0.12 -11.11%
24/06/24 0.135 +4.65%

Delayed Quote Swiss Exchange

Last update June 26, 2024 at 04:20 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
DROGVU
ISINCH1164713914
Date issued 07/03/2022
Strike 320 CHF
Maturity 24/12/2025 (541 Days)
Parity 40 : 1
Emission price 1.17 CHF
Emission volume N/A
Settlement physical
Currency CHF

Technical Indicators

Highest since issue 2.42 CHF
Lowest since issue 0.068 CHF
Spread 0.01 CHF
Spread %8.26%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus
  1. Stock Market
  2. Warrants
  3. DROGVU Warrant